BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1042 related articles for article (PubMed ID: 21700994)

  • 1. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis.
    Grazioli L; Bondioni MP; Haradome H; Motosugi U; Tinti R; Frittoli B; Gambarini S; Donato F; Colagrande S
    Radiology; 2012 Feb; 262(2):520-9. PubMed ID: 22282184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
    Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
    AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.
    Ahn SS; Kim MJ; Lim JS; Hong HS; Chung YE; Choi JY
    Radiology; 2010 May; 255(2):459-66. PubMed ID: 20413759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.
    Chong YS; Kim YK; Lee MW; Kim SH; Lee WJ; Rhim HC; Lee SJ
    Clin Radiol; 2012 Aug; 67(8):766-73. PubMed ID: 22425613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver.
    Kim JI; Lee JM; Choi JY; Kim YK; Kim SH; Lee JY; Han JK; Choi BI
    Invest Radiol; 2008 Mar; 43(3):202-10. PubMed ID: 18301317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC.
    Kim YK; Lee WJ; Park MJ; Kim SH; Rhim H; Choi D
    Radiology; 2012 Oct; 265(1):104-14. PubMed ID: 22891358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features.
    Kim JY; Kim MJ; Kim KA; Jeong HT; Park YN
    Eur J Radiol; 2012 Dec; 81(12):3877-82. PubMed ID: 22954410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
    Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
    J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
    Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
    Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
    Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
    Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI.
    Hwang J; Kim YK; Park MJ; Lee MH; Kim SH; Lee WJ; Rhim HC
    J Magn Reson Imaging; 2012 Oct; 36(4):881-9. PubMed ID: 22730271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadoxetate disodium-enhanced MR imaging: differentiation between early-enhancing non-tumorous lesions and hypervascular hepatocellular carcinomas.
    Goshima S; Kanematsu M; Watanabe H; Kondo H; Mizuno N; Kawada H; Shiratori Y; Onozuka M; Moriyama N; Bae KT
    Eur J Radiol; 2011 Aug; 79(2):e108-12. PubMed ID: 21592707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.